Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 13/20 | 0.64 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2134 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A | |
| SCHEMBL11967544 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A | |
| SCHEMBL3737 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A | |
| SCHEMBL2133 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A | |
| SCHEMBL10059 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A | |
| SCHEMBL11967563 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A | |
| SCHEMBL15809978 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A | |
| SCHEMBL15809919 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A | |
| SCHEMBL11967351 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A | |
| SCHEMBL14670 | 1.00 | TRPA1 (0.64) | TRPA1TRPC5ESR1PGRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2485737-B1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | claimed |
| EP-2485737-A1 | NOVEL TRPA1 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-08-15 | — | — | EP | claimed |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | claimed |
| WO-2011043954-A1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | claimed |
| US-8829196-B2 | TRPA1 antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829196-B2 | TRPA1 antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829196-B2 | TRPA1 antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2485737-B1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2485737-B1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | disclosed |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | disclosed |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885TRPC5 15/4885ESR1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.